2026-04-29T05:37:37Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/118402025-05-07T09:10:39Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16968

00925njm 22002777a 4500 dc Rose, Angela Mc author Kissling, Esther author Gherasim, Alin Manuel author Casado, Itziar author Bella, Antonino author Launay, Odile author Lazar, Mihaela author Marbus, Sierk author Kuliešė, Monika author Syrjänen, Ritva author Machado, Ausenda author Kurečić Filipović, Sanja author Larrauri, Amparo author Castilla Catalán, Jesús author Alfonsi, Valeria author Galtier, Florence author Ivanciuc, Alina author Meijer, Adam author Mickiene, Aukse author Ikonen, Niina author Gomez, Verónica author Lovrić Makarić, Zvjezdana author Moren, Alain author Valenciano, Marta author 2020 Background: Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2017-18, predominated by influenza B. WHO-recommended, trivalent vaccine components were lineage-mismatched for B. The I-MOVE hospital network measured 2017-18 seasonal influenza vaccine effectiveness (IVE) against influenza A(H3N2) and B among hospitalised patients (≥65 years) in Europe. Methods: Following the same generic protocol for test-negative design, hospital teams in nine countries swabbed patients ≥65 years with recent onset (≤7 days) severe acute respiratory infection (SARI), collecting information on demographics, vaccination status and underlying conditions. Cases were RT-PCR positive for influenza A(H3N2) or B; controls: negative for any influenza. "Vaccinated" patients had SARI onset >14 days after vaccination. We measured pooled IVE against influenza, adjusted for study site, age, sex, onset date and chronic conditions. Results: We included 3483 patients: 376 influenza A(H3N2) and 928 B cases, and 2028 controls. Most (>99%) vaccinated patients received the B lineage-mismatched trivalent vaccine. IVE against influenza A(H3N2) was 24% (95% CI: 2 to 40); 35% (95% CI: 6 to 55) in 65- to 79-year-olds and 14% (95% CI: -22 to 39) in ≥80-year-olds. Against influenza B, IVE was 30% (95% CI: 16 to 41); 37% (95% CI: 19 to 51) in 65- to 79-year-olds and 19% (95% CI: -7 to 38) in ≥80-year-olds. Conclusions: IVE against influenza B was similar to A(H3N2) in hospitalised older adults, despite trivalent vaccine and circulating B lineage mismatch, suggesting some cross-protection. IVE was lower in those ≥80 than 65-79 years. We reinforce the importance of influenza vaccination in older adults as, even with a poorly matched vaccine, it still protects one in three to four of this population from severe influenza. Influenza Other Respir Viruses . 2020 May;14(3):302-310. http://hdl.handle.net/20.500.12105/11840 32022450 10.1111/irv.12714 1750-2659 Influenza and other respiratory viruses Europe Hospital Influenza Older adults Test-negative design Vaccine effectiveness Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine